More on BMY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+97.4% Growth)
- Ratings (3.7 Score)
- Holders
- Dividends (0.7% Yield)
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (1/27/17 *Est.)
- Conference (12/7/2016)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 3.43B
Marketable securities 2.13B
Receivables 5.6B
Inventories 1.48B
Deferred income taxes
Prepaid expenses and other 565M
Total Current Assets 13.2B
Property, plant and equipment 4.79B
Goodwill 6.88B
Other intangible assets 1.38B
Deferred income taxes 3.53B
Marketable securities 3.04B
Other assets 918M
Total Assets 33.73B
Current Liabilities:
Short-term borrowings
Accounts payable 1.41B
Accrued expenses 4.96B
Deferred income 1.32B
Accrued rebates and returns
U.S. and foreign income taxes payable 312M
Dividends payable
Total Current Liabilities 9B
Pension, postretirement, and postemployment liabilities
Deferred income 567M
U.S. and foreign income taxes payable 905M
Other liabilities 1.64B
Long-term debt 5.84B
Total Liabilities 17.95B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 1.65B
Accumulated other comprehensive loss -2.74B
Retained earnings 33.27B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -16.8B
Total Bristol-Myers Squibb Company Shareholders' Equity 15.61B
Noncontrolling interest 168M
Total Equity 15.78B
Total Liabilities and Equity 33.73B